Compare EXAS & GRAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXAS | GRAB |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | 11267 |
| Industry | Medical Specialities | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 16.5B |
| IPO Year | 2000 | N/A |
| Metric | EXAS | GRAB |
|---|---|---|
| Price | $103.31 | $3.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $86.62 | $6.38 |
| AVG Volume (30 Days) | 1.8M | ★ 35.3M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,144,000.00 | N/A |
| Revenue This Year | $15.37 | $23.20 |
| Revenue Next Year | $12.41 | $20.23 |
| P/E Ratio | ★ N/A | $74.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.88 | $3.36 |
| 52 Week High | $104.02 | $6.62 |
| Indicator | EXAS | GRAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 30.50 |
| Support Level | $102.95 | N/A |
| Resistance Level | $103.77 | $5.25 |
| Average True Range (ATR) | 0.31 | 0.14 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 33.18 | 2.36 |
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.